Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis

References

• Waaler E. On the occurrence of a factor in human serum acti-vating the specific agglutination of sheep blood corpuscles. 1939. APMIS. 2007;115(5):422–38.
   Google Scholar
• Palosuo T, Tilvis R, Strandberg T, et al. Filaggrin related anti-bodies among the aged. Ann Rheum Dis. 2003;62(3):261–3.
   PubMed Web of Science ®Google Scholar
• Vossenaar ER, Zendman AJ, van Venrooij WJ, et al. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays. 2003;25(11):1106–18.
   PubMed Web of Science ®Google Scholar
• Steiner G, Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 2002;4(Suppl 2):S1–5.
   PubMedGoogle Scholar
• Schwab BL, Guerini D, Didszun C, et al. Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis. Cell Death Differ. 2002;9(8):818–31.
   PubMed Web of Science ®Google Scholar
• Asaga H, Yamada M, Senshu T. Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse per-itoneal macrophages. Biochem Biophys Res Commun. 1998; 243(3):641–6.
   Google Scholar
• Vossenaar ER, Radstake TR, van der Heij den A, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis. 2004;63(4): 373–81.
   Google Scholar
• Foulquier C, Sebbag M, Clavel C, et al. Peptidyl arginine dei-minase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 2007; 56(11):3541–53.
   PubMed Web of Science ®Google Scholar
• Vossenaar ER, Smeets TJ, Kraan MC, et al. The presence of citrullinated proteins is not specific for rheumatoid synovial tis-sue. Arthritis Rheum. 2004;50(11):3485–94.
   PubMed Web of Science ®Google Scholar
• Vossenaar ER, Nijenhuis S, Helsen MM, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum. 2003;48(9):2489–500.
   PubMed Web of Science ®Google Scholar
• Huizinga TW, Amos CI, Van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005;52(11):3433–8.
   Google Scholar
• Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273–81.
   PubMed Web of Science ®Google Scholar
• Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis. 1964;23:302–5.
   PubMed Web of Science ®Google Scholar
• Young BJ, Mallya RK, Leslie RD, et al. Anti-keratin antibodies in rheumatoid arthritis. Br Med J. 1979;2(6182):97–9.
   PubMed Web of Science ®Google Scholar
• Sebbag M, Simon M, Vincent C, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1995;95(6): 2672–9.
   PubMed Web of Science ®Google Scholar
• Hoet RM, Boerbooms AM, Arends M, et al. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocal-isation of the perinuclear factor and profilaggrin. Ann Rheum Dis. 1991;50(9):611–8.
   PubMed Web of Science ®Google Scholar
• Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43(1):155–63.
   PubMed Web of Science ®Google Scholar
• van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated pro-tein/peptide antibody and its role in the diagnosis and prog-nosis of early rheumatoid arthritis. Neth J Med. 2002;60(10): 383–8.
   Google Scholar
• van Venrooij WJ, Zendman AJ, Pruijn GJ. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev. 2006;6(1):37–41.
   Google Scholar
• Cantaert T, De Rycke L, Bongartz T, et al. Citrullinated proteins in rheumatoid arthritis: crucial.. .but not sufficient!. Arthritis Rheum. 2006;54(11):3381–9.
   Google Scholar
• Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol. 2007;26(2):201–4.
   Google Scholar
• del Val del Amo N, Ibanez BR, Fito MC, et al. Anti-cyclic cit-rullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol. 2006;24(3):281–6.
   PubMed Web of Science ®Google Scholar
• Mediwake R, Isenberg DA, Schellekens GA, et al. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 2001;60(1):67–8.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Palazzi C, Padula A. Hepatitis C virus and arthritis. Rheum Dis Clin North Am. 2003;29(1):111–22.
   PubMed Web of Science ®Google Scholar
• Vannini A, Cheung K, Fusconi M, et al. Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? Ann Rheum Dis. 2007;66(4):511–6.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Klotz W, Larcher H, et al. Diagnostic value of anti-bodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res 'Ther. 2006;8(4):R119.
   PubMed Web of Science ®Google Scholar
• Anzilotti C, Merlini G, Pratesi F, et al. Antibodies to viral cit-rullinated peptide in rheumatoid arthritis. J Rheumatol. 2006; 33(4):647–51.
   PubMed Web of Science ®Google Scholar
• Nielen MM, van der Horst AR, van Schaardenburg D, et al. Antibodies to citrullinated human fibrinogen (ACF) have diag-nostic and prognostic value in early arthritis. Ann Rheum Dis. 2005;64(8):1199–204.
   PubMed Web of Science ®Google Scholar
• Van der Cruyssen B, Cantaert T, Nogueira L, et al. Diagnostic value of anti-human citrullinated fibrinogen ELISA and com-parison with four other anti-citrullinated protein assays. Arthritis Res Ther. 2006;8(4):R122.
   PubMed Web of Science ®Google Scholar
• Coenen D, Verschueren P, Westhovens R, et al. Technical and diagnostic performance of 6 assays for the measurement of cit-rullinated protein/peptide antibodies in the diagnosis of rheuma-toid arthritis. Clin Chem. 2007;53(3):498–504.
   PubMed Web of Science ®Google Scholar
• Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741–9.
   Google Scholar
• Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380–6.
   PubMed Web of Science ®Google Scholar
• van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Auto-antibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50(3):709–15.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.
   PubMed Web of Science ®Google Scholar
• Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(1):34–45.
   PubMed Web of Science ®Google Scholar
• Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic labora-tory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):196–201.
   PubMed Web of Science ®Google Scholar
• Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010;69(7):1333–7.
   PubMed Web of Science ®Google Scholar
• Chibnik LB, Mandl LA, Costenbader KH, et al. Comparison of threshold cutpoints and continuous measures of anti-cyclic cit-rullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol. 2009;36(4):706–11.
   PubMed Web of Science ®Google Scholar
• Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrulli-nated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2010;69(3):490–4.
   PubMed Web of Science ®Google Scholar
• Verpoort KN, der Jol-van Zijde CM, der Papendrecht-van Voort EA, et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 2006; 54(12):3799–808.
   Google Scholar
• Schuerwegh AJ, Ioan-Facsinay A, Dorjee AL, et al. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci USA. 2010;107(6): 2586–91.
   PubMed Web of Science ®Google Scholar
• van der Woude D, Syversen SW, van der Voort El, et al. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):1110–6.
   PubMed Web of Science ®Google Scholar
• Takizawa Y, Suzuki A, Sawada T, et al. Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis. 2006;65(8):1013–20.
   PubMed Web of Science ®Google Scholar
• Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007;56(8):2503–11.
   PubMed Web of Science ®Google Scholar
• Kinloch A, Tatzer V, Wait R, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther. 2005;7(6):R1421–9.
   PubMed Web of Science ®Google Scholar
• van de Stadt LA, van der Horst AR, de Koning MH, et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis. 2011;70(1):128–33.
   PubMed Web of Science ®Google Scholar
• van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis. 2010;69(8): 1554–61.
   PubMed Web of Science ®Google Scholar
• Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked dif-ferences in fine specificity and isotype usage of the anti-citrulli-nated protein antibody in health and disease. Arthritis Rheum. 2008;58(10):3000–8.
   Google Scholar
• Clavel C, Nogueira L, Laurent L, et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor Ha engagement by rheumatoid arthritis-specific autoan-tibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 2008;58(3):678–88.
   PubMed Web of Science ®Google Scholar
• Arnold JN, Wormald MR, Sim RB, et al. The impact of glyco-sylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.
   PubMed Web of Science ®Google Scholar
• Trouw LA, Haisma EM, Levarht EW, et al. Anti-cyclic citrulli-nated peptide antibodies from rheumatoid arthritis patients acti-vate complement via both the classical and alternative pathways. Arthritis Rheum. 2009;60(7):1923–31.
   PubMed Web of Science ®Google Scholar
• van de Geijn FE, Wuhrer M, Selman MH, et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res 'Ther. 2009;11(6):R193.
   PubMed Web of Science ®Google Scholar
• Scherer HU, van der Woude D, Ioan-Facsinay A, et al. Glycan profiling of anti-citrullinated protein antibodies (ACPA) isolated from human serum and synovial fluid. Arthritis Rheum. 2010; 62(6):1620–9.
   Google Scholar
• Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50(7):2072–81.
   PubMed Web of Science ®Google Scholar
• van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537–46.
   PubMed Web of Science ®Google Scholar
• van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2006;54(4):1117–21.
   PubMed Web of Science ®Google Scholar
• van der Helm-van Mil AH, Verpoort KN, le Cessie S, et al. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum. 2007;56(2):425–32.
   PubMed Web of Science ®Google Scholar
• van Dongen H, van Aken J, Lard LR, et al. Efficacy of metho-trexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56(5):1424–32.
   PubMed Web of Science ®Google Scholar
• Emery P, Durez P, Dougados M, et al. Impact of T-cell costi-mulation modulation in patients with undifferentiated inflamma-tory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69(3):510–6.
   PubMed Web of Science ®Google Scholar
• Verstappen SM, McCoy MJ, Roberts C, et al. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis. 2010;69(3):503–9.
   PubMed Web of Science ®Google Scholar
• Machold KP, Landewe R, Smolen JS, et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, random-ised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis. 2010;69(3):495–502.
   PubMed Web of Science ®Google Scholar
• Saleem B, Mackie S, Quinn M, et al. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferen-tiated arthritis prevent progression to rheumatoid arthritis? Ann Rheum Dis. 2008;67(8):1178–80.
   PubMed Web of Science ®Google Scholar
• Koffeman EC, Genovese M, Amox D, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 2009;60(11):3207–16.
   PubMed Web of Science ®Google Scholar